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Purpose. Studies were performed to examine hemodynamic and renal function before and after acute induction of the endogenous
CO system with delta-aminolevulinic acid (DALA), which drives HO activity. Methods. In vivo studies were conducted on Inactin-
anesthetized male Sprague Dawley rats (250–300g) either with or without chronic pretreatment with L-NAME (50mg/Kg, q12
hours x4d). Results.D A L A( 8 0 μmol/Kg, IV bolus) administration acutely increased endogenous CO production and HO-1
protein. In untreated and L-NAME-pretreated rats, DALA did not alter BP, GFR, or RBF but increased UF, UNaV, and UKV
(untreated: Δ108.8 ± 0.28%, 172.1 ± 18.4%, and 165.2 ± 45.9%; pretreated: Δ109.4 ± 0.29%, 187.3 ± 26.9%, and 197.2 ± 45.7%).
Acute administration of biliverdin (20mg/kg, IV) and bilirubin (30mg/kg, IV) to similarly treated animals did not alter UF, UNaV,
and UKV. Conclusion. These results demonstrate that heme oxygenase induction increases urine and electrolyte excretion and
suggest a direct tubular action of endogenous carbon monoxide.
1.Introduction
Metabolic degradation of heme by heme oxygenase (HO)
yields three products; biliverdin, ferrous iron, and carbon
monoxide (CO) [1]. Currently, two major isoforms of the
HO enzyme have been recognized, the inducible HO-1 and
the constitutive HO-2. Both isoforms have been reported to
be present in the kidneys [1–3]. Several biological stressors,
such as oxidative stress, ischemia, and hypertension, are
known to increase HO-1 levels [4–6]. In contrast, the HO-
2 isoform is constitutively expressed and is present in high
concentrationsinthekidney,aswellasinothervascularbeds
and tissues [7] .A l t e r a t i o n si nH Ol e v e l sh a v eb e e nd e m o n -
strated to alter CO concentration, in addition to having pro-
found eﬀects on vascular tone [8, 9].
Current literature supports both an endothelial-depend-
ent vasoconstrictor eﬀect of CO and an endothelial-inde-
pendent vasorelaxation [10, 11]. CO-mediated vasoconstric-
tion is via inhibition of nitric oxide synthase (NOS) [11, 12].
CO also promotes endothelium-independent vasodilation
through the activation of soluble guanylyl cyclase, stimu-
lation of K channels, and inhibition of the cytochrome-
P450-dependent monooxygenase system in vascular smooth
muscle cells [10, 13]. Increases in endogenous CO levels
produce a decrease in blood pressure in several forms of
hypertension, while HO inhibition increases arterial blood
pressure [4, 14–17]. Regional diﬀerences in renal blood ﬂow
(RBF) have been demonstrated with increases in the medulla
without signiﬁcant increases in cortical blood ﬂow during
heme-induced increases in CO [13] .O t h e rs t u d i e sh a v en o t
shown signiﬁcant alterations in renal vascular resistance
during alterations in CO levels, thus controversy does exist
in the literature as it relates to the ability of CO to regulate
renal vascular resistance [18].2 International Journal of Hypertension
Increases in HO activity via heme administration pro-
mote vasorelaxation and produce diuresis and natriuresis
[19]. In addition, several studies have identiﬁed an antiox-
idant role for bilirubin and biliverdin during stress [20,
21]. However, the mechanisms of HO-mediated eﬀects on
renal function have yet to be elucidated. Because the HO-
mediated diuretic and natriuretic eﬀects were observed
concomitantly with an increase in RBF, it is possible that
alterations in renal hemodynamics mediate the increase in
UFandsodiumexcretion.Ithasalsobeenreportedthatrenal
medullary HO plays a key role in the regulation of pressure
natriuresis and, thus, the control of arterial blood pressure
[22]. Macula densa cells have been reported to express HO-
1 and HO-2, and stannous mesoporphyrin, an inhibitor
of HO, was shown to augment tubuloglomerular feedback
in both in vitro and in vivo studies [23]. In addition, we
recently reported that CO inhibition promotes antidiuresis
and antinatriuresis independent of vascular or systemic
changes [24]. Therefore, we hypothesized that increased
levels of endogenous CO promote natriuresis and diuresis
independent of inhibition of nitric oxide synthase (NOS)
and alterations in RBF. To examine this hypothesis, the
potential direct tubular eﬀects of a heme precursor, delta-
aminolevulinic acid (DALA), which drives HO activity, were
studied using a dose of DALA that does not elicit changes
in renal hemodynamic function in control and L-NAME
treated rats.
2. Methods
2.1. Materials. DALA was purchased from Frontier Scientiﬁc
(Logan, UT, USA). Inactin (thiobutabarbital sodium), N-
Nitro-L-Arginine Methyl Ester (L-NAME), bilirubin, and
para-aminohippuric acid (PAH) were obtained from Sigma-
Aldrich (St. Louis, MO, USA). Albumin was purchased
from EMD Biosciences Inc. (San Diego, CA, USA). Inulin
was purchased from Fresenius Kabi UK Ltd. (Runcorn,
Cheshire). Plasma Renin Activity (PRA) kits were purchased
from Diasorin Inc. (Stillwater, MN, USA). Biliverdin was
purchased from MP Biochemicals, LLC (Solon, OH, USA).
All other chemicals were purchased from Fisher Scientiﬁc
(Houston, TX, USA). DALA stock solution (800mmol/L)
was prepared in saline on the day of the experiments. L-
NAME (50mmol/L) was dissolved in saline immediately
before intraperitoneal injection. All other solutions were
freshly prepared on the day of the experiment.
2.2. Animals. Male Sprague-Dawley rats (250–350g; n =
146, Harlan, Indianapolis, IN, USA) were used (n = 32).
ThisprotocolwasapprovedbytheTulaneSchoolofMedicine
and University of Louisiana at Monroe Institutional Animal
Care and Use Committee. Prior to experiments, rats were
housed in a controlled environment and had free access to
commercial rat chow and tap water. Subsets of animals were
chronically treated every 12 hours for four days with an
inhibitorofNOS[25],L-NAME(50mg/kg,IP).Tominimize
postprandial sodium excretion variability, animals were de-
prived of food for 12 hours before experiments.
Subsets of animals were chronically treated with L-
NAME every 12 hours for four days. After anesthetization
with Inactin and surgical preparation, rats were allowed to
stabilize for 45min. After this initial stabilization period,
a 30-minute control period was performed and urine was
collected. L-NAME-treated and -untreated animals were
thenacutelyadministeredDALA(80μmol/kg,IV),biliverdin
(20mg/kg, IV), bilirubin (30mg/kg, IV), or vehicle (1mL
saline, IV), and an additional 30-minute treatment period
was performed. The doses of biliverdin and bilirubin were
chosen from previous studies where an antioxidant eﬀect
was observed [20, 21]. Mean arterial pressures (MAP), heart
rates (HR), and RBF were measured during both the 30-
minute control and treatment periods. After the experimen-
talprotocolswerecompleted,renalvascularresistance(RVR)
was calculated as the pressure to ﬂow ratio and expressed as
“mmHg/(mL/min)”.
2.3. Experimental Procedures. Rats were anesthetized with a
single injection of thiobutabarbital sodium (120mg/kg; IP),
and a tracheal tube was inserted to maintain an open airway.
Fluid ﬁlled catheters (PE-50 tubing ﬁlled with heparinized
saline) were inserted into a carotid artery and a jugular vein
to allow for continuous monitoring of MAP and HR, and for
intravenous administration of drugs, respectively. The arte-
rial catheter was connected to a pressure transducer (model
TSD104A, Biopac Systems, Santa Barbara, CA, USA), and
the venous catheter was connected to a Sage microinfusion
pump (Orion Research, Inc., model M361, Boston, MA,
USA) set at 1mL/hr saline infusion rate. A bladder cannula
was inserted to allow urine collection for determination of
urine ﬂow and concentrations of sodium and potassium
(Flame Photometry; Instrumentation Laboratories, IL 943).
A ﬂank incision was made to expose the left kidney and renal
artery.RBFwasmeasuredwitharenalﬂowprobe(Transonic,
Ithaca, NY, USA) placed around the renal artery and con-
nectedtoaTransonic-T206synchronizedﬂowmetercoupled
to a polygraph system (model MP100, Biopac System).
2.4. Glomerular Filtration Rate. In a subset (n = 24) of anes-
thetized rats, the experiments were repeated with an addi-
tional catheter inserted into the right femoral vein to infuse
inulin, para-amino hippuric acid, and albumin. Plasma and
urine sodium and potassium concentrations were deter-
mined by ﬂame photometry, and inulin concentrations were
measuredcolorimetricallytodetermineglomerularﬁltration
rate(GFR)[26].RVRandfractionalsodiumexcretion(FENa)
were calculated according to standard formulas. The renal
excretion data from this subset of animals were not included
in the ﬁnal measures due to the diﬀerent handling of these
animals (additional catheter, and albumin, PAH, and inulin
infusion). However, the excretory data from these animals
followed the same trends as the reported data.
2.5. Plasma Renin Activity. Plasma renin activity (PRA) was
measured with a commercially available assay kit (Gamma
Coat PRA Assay Kit) [27]. Brieﬂy, DALA (80μmol/kg; IP)
was infused into L-NAME- (50mg/Kg; IP) pretreated orInternational Journal of Hypertension 3
untreated rats and PRA was measured to determine if altered
CO levels had any eﬀect on the renin-angiotensin system.
PRAwasdeterminedbytheradioimmunoassaygenerationof
angiotensin I. Given the noted experimental diﬃculties with
measuring PRA in whole animals, we did not perform clear-
ance measurements or CO measurements in these animals.
2.6. Determination of the Eﬀect of DALA to Increase CO
Excretion. A subset of awake Sprague-Dawley rats (n = 12)
that did not receive any surgical treatments were infused
with DALA (80μmol/kg, IV) to increase HO activity, both
with and without chronic L-NAME pretreatment every 12
hours for 4 days. Animals were placed in an acrylic airtight
chamber with the outﬂow leading to a heated mercuric oxide
bed coupled with a gas chromatograph (Peak, Mountain
View, CA, USA) for the determination of CO concentration,
detailed elsewhere [28, 29]. The chamber was continuously
purged with puriﬁed air and the outﬂow sampled for CO
concentrationat2minintervals.Aftera10minequilibration
p e r i o d ,t h ea v e r a g eo ff o u rm e a s u r e m e n t sw a su s e dt o
calculate the CO excretion rate for the whole animal.
2.7. Determination of Renal HO-1 Levels. In a subset (n =
14) of similarly treated anesthetized animals, the experi-
mental protocols were repeated to determine the ability of
DALA infusion to alter renal HO-1 levels. Renal HO-1 levels
were measured by commercially available ELISA kits pur-
chased from Stressgen. Kidneys from L-NAME-pretreated
and untreated rats were removed and ﬂash frozen in liquid
nitrogen and suspended in 1X extraction reagent and pro-
tease inhibitor. Once the kidney tissues were homogenized,
the ELISA sandwich immunoassay was preformed and the
level of HO-1 protein present in the kidney was determined.
3.DataAnalysis
Data were expressed as mean ± SEM. Data were analyzed
by analysis of variance (ANOVA) followed by orthogonal
contrast when appropriate (SYSTAT). Bonferroni correction
was employed in the ﬁnal analysis of completed series (α =
0.05) [30].
4. Results
4.1. Whole Animal CO Excretion. Acute administration of
the heme precursor, DALA (80μmol/kg, IP), to untreated
animals produced a signiﬁcant increase in expired CO levels
(Δ63.9 ± 1.6%, n = 3) (Figure 1). This eﬀect was similar
to a higher dose of DALA (800μmol/kg, IP) (Jackson et al,
unpublished results). This increase in expired CO was not
aﬀected by L-NAME (50mg/Kg; IP) pretreatment (Δ67.6 ±
1.9%, n = 3) (Figure 1).
4.2. Renal HO-1 Levels. Acute administration of DALA
(80μmol/kg, IV) in untreated and L-NAME-pretreated
anesthetized rats produced a signiﬁcant increase in renal
HO-1 levels in untreated (Δ50 ± 0.56%, n = 7) (Figure 2)
and L-NAME-treated (Δ60 ± 0.64%, n = 7) (Figure 2)
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Figure 1: DALA (80μmol/kg; IV) infusion acutely increased
expired CO levels in L-NAME-treated and -untreated awake rats.
Values are mean ± SE; n = 6e a c h .
Heme oxygenase measurements before and after DALA
Control
DALA
Vehicle L-NAME
50 mg/Kg; IP
H
O
-
1
 
(
n
g
/
m
g
)
0
3
6
9
12
15
∗
∗
Figure 2: In anesthetized rats, DALA (80μmol/kg; IV) acutely
increased renal HO-1 levels in vehicle (left) and L-NAME-treated
(right)rats.(
∗P < 0.05,pre-versus30minpost-DALA;n = 6each).
rats. L-NAME pretreatment produced a signiﬁcant increase
in renal HO-1 levels, as compared to untreated animals
(Figure 2); however, DALA increased renal HO-1 levels
to a similar extent as in untreated animals. There were
no signiﬁcant diﬀerences in hematocrit pre- and post-
DALA administration in both the L-NAME-pretreated and
-untreated animals.
4.3. Renal Functional Responses. The subsequent values were
obtained during the 30min experimental period following
administration of DALA (80μmol/kg; IP), biliverdin (20mg/
kg), bilirubin (30mg/kg), or vehicle in L-NAME-(50mg/kg;
IP) treated and untreated animals. In animals without pre-
treatment, DALA did not exert signiﬁcant systemic or renal
hemodynamic eﬀects (Table 1), but there were signiﬁcant
increases in urine ﬂow and sodium and potassium excretion
(Δ108.8±0.28%, 172.1±18.4%, and 165.2±45.9%: n = 20)4 International Journal of Hypertension
Table 1: Eﬀects of DALA (80 μmol/kg, IV), biliverdin (20mg/Kg, IV), and bilirubin (30mg/Kg, IV) administration on heart rate (HR),
mean arterial pressure (MAP), renal blood ﬂow (RBF), and calculated renal vascular resistance (RVR).
HR MAP RBF RVR
N (bpm) (mmHg) (ml/min) (mmHg/ml/min)
No pretreatment
Control 385 ±0.13 110 ±0.06 5.6 ±0.12 19.6 ±0.14
Vehicle 8 395 ±0.16 114 ±0.08 5.8 ±0.14 19.7 ±0.11
DALA 8 382 ±0.12 118 ±0.09 5.9 ±0.16 20.0 ±0.18
Biliverdin 8 396 ±0.25 113 ±0.04 6.1 ±0.15 18.6 ±0.21
Bilirubin 8 398 ±0.18 109 ±0.15 5.4 ±0.14 20.1 ±0.24
Chronic L-NAME
Control 398 ±0.19 153 ±0.05 5.5 ±0.14 27.8 ±0.28
Vehicle 8 400 ±0.23 150 ±0.12 5.2 ±0.18 28.8 ±0.20
DALA 8 403 ±0.14 155 ±0.24 5.8 ±0.21 28.2 ±0.38
Biliverdin 8 396 ±0.19 158 ±0.15 5.5 ±0.14 28.7 ±0.47
Bilirubin 8 399 ±0.24 152 ±0.05 5.1 ±0.14 29.2 ±0.32
(Figure 3). Biliverdin (20mg/kg) and bilirubin (30mg/kg)
did not cause signiﬁcant systemic or renal hemodynamic
eﬀects (Table 1) and any signiﬁcant changes in urine ﬂow
or sodium, and potassium excretion (Table 3). In rats pre-
treated chronically with L-NAME, there was a signiﬁcant
increase in MAP (100mmHg versus 150mmHg) but DALA
administration had no signiﬁcant eﬀects on MAP, HR, RBF,
or RVR (Table 1). However, DALA signiﬁcantly increased
urine ﬂow and sodium and potassium excretion (Δ109.4 ±
0.29%,187.3±26.9%,and197.2±45.7%:n = 20)(Figure 4).
Biliverdin (20mg/kg) and bilirubin (30mg/kg) did not exert
signiﬁcant eﬀects on MAP, HR, RBF, or RVR (Table 1)
and any signiﬁcant eﬀects on urinary volume, sodium and
potassium excretion (Table 3). There were no signiﬁcant dif-
ferences between the urine ﬂow and electrolyte excretion in
the L-NAME-untreated and -treated animals. Vehicle treat-
ment had no eﬀect in either group. DALA had no eﬀects
on glomerular ﬁltration in either L-NAME-treated or -un-
treated rats (Table 2: n = 24).
4.4. Plasma Renin Activity. In untreated rats given DALA,
no signiﬁcant diﬀerences in plasma renin activity (PRA)
were evident (Figure 5; n = 25). Similarly DALA did
not signiﬁcantly alter PRA in L-NAME-pretreated animals
(Figure 5; n = 21).
5. Discussion
The present study investigated the role of increases in
endogenous CO on renal excretory function. The heme pre-
cursor,DALA, increased expired CO levelsin both L-NAME-
treated and -untreated animals. DALA, which promotes the
generation of endogenous CO, increased volume and elec-
trolyte excretion in both L-NAME-treated and -untreated
animals. Acute increases in endogenous CO formation were
notaccompaniedbyanysigniﬁcantdiﬀerencesinsystemicor
renal hemodynamic function in that a low dose of DALA was
speciﬁcally chosen to avoid alterations in renal or systemic
hemodynamics. There were also no signiﬁcant changes in
GFR with DALA infusion in L-NAME-treated or -untreated
animals.
Increases in heme oxygenase activity, promote an equim-
olar elevation in carbon monoxide, iron, and biliverdin [31].
Biliverdin is quickly converted to bilirubin [31]. Current lit-
eraturewouldsupportanantioxidant roleforbothbiliverdin
and bilirubin [20, 21]. To examine the potential role of these
heme products to alter renal excretory function, a subset of
animals was given biliverdin or bilirubin and the study was
repeated. However, no signiﬁcant diﬀerences in renal or sys-
temichemodynamicswereobservedand,similarly,nosignif-
icant diﬀerences in renal excretory function were observed,
thus, suggesting that the observed increases in urine ﬂow
and sodium and potassium excretion were due to carbon
monoxide. The negative results observed with biliverdin and
bilirubin suggest that they are not involved in the heme-
oxygenase-mediated diuretic eﬀects; however, the current
study cannot rule out the importance of these metabolites
in the kidney in that renal intracellular concentrations of
biliverdin and bilirubin were not measured.
DALA has been previously shown to increase HO activity
in rats [32]. We have reported that DALA also increases
expired CO levels, as well. Thus, DALA, a substrate that
drives heme formation and increases HO activity, can
produce signiﬁcant increases in endogenous CO formation.
DALA administration was observed to signiﬁcantly increase
HO-1 levels both in the presence and absence of an intact
NOsystem.L-NAMEadministrationincreasedbaselineHO-
1 levels, perhaps due to the observed elevation in MAP.
Importantly, the ability of DALA administration to increase
HO-1 levels was not aﬀected by L-NAME.
The current study used DALA to drive CO formation in
that iron loading can lead to eﬀects on the vasculature that
are independent of the CO system. Iron loading can occur,
when one increases CO formation via heme administration
orCOreleasingmolecules[32].Thecurrentdatasupportthe
hypothesis that CO increases water and electrolyte excretion
independent of changes in systemic or renal hemodynamics.International Journal of Hypertension 5
Table 2: Eﬀects of increases in endogenous CO (DALA 80μmol/Kg, IV) on glomerular ﬁltration rate (GFR), urine ﬂow (UF), sodium
excretion (UNaV), fractional excretion of sodium (FENa), and urinary potassium (UKV).
UF GFR UNaVF E Na UKV
N (μl/min) (ml/min) (μmol/min) (%) (μmol/min)
No pretreatment
Control 6 6.49 ±0.47 1.11 ±0.05 0.59 ±0.15 0.50 ±0.03 0.14 ±0.04
Vehicle 6 6.49 ±0.48 1.10 ±0.08 0.61 ±0.08 0.51 ±0.16 0.15 ±0.03
Control 6 6.51 ±0.50 1.12 ±0.11 0.60 ±0.11 0.53 ±0.12 0.14 ±0.01
DALA 6 13.99 ±1.84
∗ 1.10 ±0.06 1.19 ±0.03
∗ 0.78 ±0.01
∗ 0.90 ±0.13
∗
Chronic L-NAME
Control 6 7.37 ±0.73 1.11 ±0.02 0.68 ±0.13 0.50 ±0.01 0.23 ±0.13
Vehicle 6 7.43 ±0.78 1.15 ±0.18 0.68 ±0.04 0.49 ±0.05 0.23 ±0.02
Control 6 7.51 ±0.54 1.12 ±0.17 0.67 ±0.11 0.50 ±0.02 0.24 ±0.04
DALA 6 14.37 ±0.41
∗ 1.11 ±0.10 1.22 ±0.02
∗ 0.80 ±0.12
∗ 1.09 ±0.19
∗
Table 3: Eﬀects of biliverdin (20mg/Kg, IV) and bilirubin (30mg/Kg, IV) administration on urine ﬂow (UF), sodium excretion (UNaV)and
urinary potassium (UKV).
UF UNaVU KV
N (μl/min) (μmol/min) (μmol/min)
No pretreatment
Control 6 2.50 ±0.30 0.17 ±0.02 0.49 ±0.06
Biliverdin 6 2.10 ±0.12 0.16 ±0.01 0.46 ±0.05
Control 6 2.80 ±0.15 0.19 ±0.12 0.46 ±0.01
Bilirubin 6 2.90 ±0.21 0.16 ±0.04 0.41 ±0.09
Chronic L-NAME
Control 6 3.40 ±0.25 0.15 ±0.02 0.41 ±0.06
Biliverdin 6 3.30 ±0.39 0.17 ±0.02 0.40 ±0.35
Control 6 3.20 ±0.51 0.18 ±0.02 0.46 ±0.05
Bilirubin 6 3.30 ±0.37 0.18 ±0.02 0.45 ±0.03
The increases in urine ﬂow and electrolyte excretion were
still present during NOS inhibition by L-NAME, indicating
once again that the CO eﬀects on urine ﬂow and electrolyte
excretion are not simply due to alterations in the nitric
oxide (NO) system. Furthermore, DALA administration did
not signiﬁcantly alter PRA, thus CO enhancement of renal
excretion was not via suppression of the renin angiotensin
system. We recently reported that inhibition of endogenous
CO increased PRA in untreated rats [24]. This increase in
PRA was abolished by L-NAME pretreatment [24]. However,
endogenous CO eﬀects on the juxtaglomerular cells could be
maximal even at basal conditions; therefore, increasing CO
formation by DALA would not aﬀect PRA.
In previous research, an increase in CO concentration
elicited through heme administration was shown to decrease
RVR, increase RBF, and urine ﬂow and sodium excretion
[33]. Similar results can be observed with CO releasing mol-
ecules. Pretreatment with the HO inhibitor, SnMP, abolished
the diuretic and natriuretic eﬀects of heme but did not aﬀect
the increases in RBF. The heme-induced changes in renal
hemodynamic parameters could perhaps be attributed to
diﬀerences in agents (DALA versus heme) and/or concentra-
tions. Regional diﬀerences in HO activity in the kidney have
been reported, where medullary heme oxygenase contributes
to pressure natriuresis and arterial blood pressure in the
absence of any signiﬁcant changes in cortical HO activity
[22]. As previously stated, low concentrations of DALA were
employed to avoid hemodynamic changes in the present
study. Therefore, DALA-induced increases in urine ﬂow and
electrolyte excretion were not accompanied by any changes
in renal hemodynamic function. However, medullary blood
ﬂow was not measured and we cannot exclude the possibility
of small increases in medullary BF to the diuretic and
natriuretic responses. Collectively these data suggest that CO
alters water and electrolyte excretion independent of changes
in NO and renal hemodynamic function and suggests that
t h i sr e s p o n s ei sd u et oad i r e c tr e n a lt u b u l a re ﬀect.
Previous studies have demonstrated CO’s ability to pro-
mote vasoconstriction via inhibition of NOS [19, 34]. How-
ever, in the present study, such an interaction between
the two systems in acutely regulating water and electrolyte
excretion was not observed. Thus, it is possible that in organ
systems with a large capacity to autoregulate, such as the
brain, heart, and kidney, CO inhibition of NO does not play
a major role in establishing normal basal vascular tone. CO
was able to promote water and electrolyte excretion without6 International Journal of Hypertension
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Figure 3: In anesthetized rats, DALA (80μmol/kg) IV infusion
acutely increased urine ﬂow and sodium and potassium excretion
in untreated rats. Values are mean ± SE; n = 20.
∗P < 0.05 versus
control (vehicle infusion).
aﬀecting renal hemodynamics, which suggests an alternate
pathway for CO regulation of renal excretory function.
Thus, CO could have direct eﬀects on the tubules to alter
water and electrolyte excretion. As a low dose of DALA
was administered to avoid altering renal hemodynamics, the
results suggest that the alterations in renal excretory function
are most likely mediated via a direct tubular eﬀect to inhibit
sodium transport in that sodium and potassium excretion
were enhanced during DALA administration.
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Figure 4:Inanesthetizedrats,acuteIVinfusionofDALA(80μmol/
kg) increased urine ﬂow, urinary sodium, and urinary potassium
excretion in L-NAME-pretreated animals. Values are mean ± SE;
n = 20.
∗P < 0.05 versus control (vehicle infusion).
6. Signiﬁcanceof the Study
Previous studies have demonstrated that increases in HO
activity can promote signiﬁcant diuresis [33]. Since heme
administration was accompanied by a signiﬁcant increase in
blood pressure, it could not be established if the observed
diuresis was due to a direct tubular action or simply due
to an increase in perfusion pressure. In addition, it was not
shown if the diuresis was due to CO or one of the other HOInternational Journal of Hypertension 7
Eﬀects of increased CO levels on PRA
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Figure 5: Acute administration of DALA (80μmol/kg; IP) did not
exertsigniﬁcant eﬀectsonplasmareninactivity(PRA)inL-NAME-
pretreated and -untreated rats. Vehicle and DALA changes in PRA
wereobservedfor30-minuteperiods.Valuesaremean±SE;n = 46.
metabolites. In the current study, we demonstrate a direct
tubular action of HO induction in the absence of alterations
in renal hemodynamic function. Furthermore, the negative
results with biliverdin and bilirubin administration suggest a
tubular role of CO as a novel diuretic and therapeutic target
to treat hypertension.
7. Conclusion
In summary, the present data indicate that an induction in
HO-1increaseswaterandelectrolyteexcretionintheabsence
of alterations in renal hemodynamics, PRA, GFR, or NO
production,thus,suggestingadirecttubularroleforendoge-
nous CO in the control of sodium excretion.
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